B cell checkpoints in autoimmune rheumatic diseases

被引:76
|
作者
Rubin, Samuel J. S. [1 ,2 ,3 ]
Bloom, Michelle S. [1 ,2 ,3 ]
Robinson, William H. [1 ,2 ,3 ]
机构
[1] Stanford Univ, Sch Med, Immunol Program, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Med, Sch Med, Div Immunol & Rheumatol, Stanford, CA 94305 USA
[3] VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
SYSTEMIC-LUPUS-ERYTHEMATOSUS; FC-GAMMA RECEPTOR; T-CELL; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; IMMUNE-COMPLEX; PLASMA-CELLS; IN-VITRO; ANTIGEN RECEPTOR; ANKYLOSING-SPONDYLITIS;
D O I
10.1038/s41584-019-0211-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
B cells have important functions in the pathogenesis of autoimmune diseases, including autoimmune rheumatic diseases. In addition to producing autoantibodies, B cells contribute to autoimmunity by serving as professional antigen-presenting cells (APCs), producing cytokines, and through additional mechanisms. B cell activation and effector functions are regulated by immune checkpoints, including both activating and inhibitory checkpoint receptors that contribute to the regulation of B cell tolerance, activation, antigen presentation, T cell help, class switching, antibody production and cytokine production. The various activating checkpoint receptors include B cell activating receptors that engage with cognate receptors on T cells or other cells, as well as Toll-like receptors that can provide dual stimulation to B cells via co-engagement engagement with the B cell receptor. Furthermore, various inhibitory checkpoint receptors, including B cell inhibitory receptors, have important functions in regulating B cell development, activation and effector functions. Therapeutically targeting B cell checkpoints represents a promising strategy for the treatment of a variety of autoimmune rheumatic diseases.
引用
收藏
页码:303 / 315
页数:13
相关论文
共 50 条
  • [1] B cell checkpoints in autoimmune rheumatic diseases
    Samuel J. S. Rubin
    Michelle S. Bloom
    William H. Robinson
    Nature Reviews Rheumatology, 2019, 15 : 303 - 315
  • [2] Activation Markers on B and T Cells and Immune Checkpoints in Autoimmune Rheumatic Diseases
    Gerasimova, Elena V.
    Tabakov, Dmitry V.
    Gerasimova, Daria A.
    Popkova, Tatiana V.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)
  • [3] B cell depletion in autoimmune rheumatic diseases
    Pitashny, M
    Shoenfeld, Y
    AUTOIMMUNITY REVIEWS, 2005, 4 (07) : 436 - 441
  • [4] Checkpoints controlling the induction of B cell mediated autoimmunity in human autoimmune diseases
    Reijm, S.
    Kissel, T.
    Toes, R. E. M.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2020, 50 (12) : 1885 - 1894
  • [5] Cell therapy in rheumatic Autoimmune diseases
    Hiepe, F.
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2012, 62 : S14 - S15
  • [6] Stem cell transplantation for rheumatic autoimmune diseases
    Huegle, Thomas
    van Laar, Jacob M.
    ARTHRITIS RESEARCH & THERAPY, 2008, 10 (05)
  • [7] Stem cell transplantation for rheumatic autoimmune diseases
    Thomas Hügle
    Jacob M van Laar
    Arthritis Research & Therapy, 10
  • [8] Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies
    Meffre, Eric
    O'Connor, Kevin C.
    IMMUNOLOGICAL REVIEWS, 2019, 292 (01) : 90 - 101
  • [9] Autoimmune Rheumatic Diseases 1 Clinical aspects of autoimmune rheumatic diseases
    Goldblatt, Fiona
    O'Neill, Sean G.
    LANCET, 2013, 382 (9894): : 797 - 808
  • [10] Methylation of T and B Lymphocytes in Autoimmune Rheumatic Diseases
    Deng, Tiantian
    Wang, Zihan
    Geng, Qishun
    Wang, Zhaoran
    Jiao, Yi
    Diao, Wenya
    Xu, Jiahe
    Deng, Tingting
    Luo, Jing
    Tao, Qingwen
    Xiao, Cheng
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2024, 66 (03) : 401 - 422